Head and Neck Cancer Clinical Trial
Official title:
A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients With Metastatic or Advanced, Locally, Recurrent Head and Neck Cancer
The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer. Patients with advanced or recurrent head and neck cancer, which is untreatable by surgery or radiation therapy are eligible for this study. Standard treatment for advanced or recurrent head and neck cancer involves the use of chemotherapy.
Approximately 28,900 patients will be diagnosed with squamous cell cancers of the oral
cavity and pharynx in the year 2002. Of these, an estimated 7,400 patients will present with
metastases or develop recurrent disease, which is not amenable to surgery or radiation
therapy. Palliative chemotherapy is thus the only treatment option. Currently, combinations
of cisplatin and 5-fluorouracil are used as first line treatment strategies, with median
times to progression of 2.5 to 3 months and median survival rates of 5 to 7 months. The time
to achieve maximum response with combination therapy is on average 4 months.
Taxanes, with their unique mechanism of microtubule stabilization, have demonstrated
response rates similar to standard, first line combination regimens. Several phase II
studies have evaluated the efficacy of single agent docetaxel in head and neck cancer
patients. Cumulative response rates were approximately 30%, with higher response rates
observed in patients receiving no prior chemotherapy. Docetaxel has also been used in
combination with cisplatin and cisplatin and 5-fluorouracil. Although response rates with
such combination regimens were superior to the use of single agent docetaxel, grade 3 and 4
toxicities were also more prevalent.
Capecitabine (Xeloda®), a fluoropyrimidine carbamate, is an oral prodrug, which is converted
in tumor tissues to 5-fluorouracil through multienzymatic activation. Capecitabine (Xeloda®)
has documented activity in breast and colorectal cancers and is widely administered. Because
5-fluorouracil has efficacy in the treatment of head and neck cancer, it is reasonable to
consider that such tumors will respond to capecitabine. To date, there are no published
trials using capecitabine (Xeloda®) in the treatment of metastatic head and neck cancer
patients. However, clinical trials are ongoing in the U.S. and Europe with promising
results.
In preclinical models, a synergistic interaction between capecitabine and docetaxel has been
documented. One possible explanation for the synergy is that docetaxel up-regulates tumor
levels of thymidine phosphorylase, the enzyme essential for the activation of capecitabine
and 5'-dFUrd to 5-fluorouracil. Clinically, O'Shaughnessy, et al. recently reported improved
survival with docetaxel/capecitabine combination therapy in patients with metastatic breast
cancer, who previously failed anthracycline-containing chemotherapy. In this phase III
study, patients were stratified according to previous exposure to paclitaxel and then
randomized to capecitabine (Xeloda®) (1250 mg/m2 twice daily, days 1-14) plus docetaxel (75
mg/m2 day 1, repeated every 21 days) versus docetaxel alone. Grade 3 and 4 toxicities were
more common in the docetaxel/capecitabine combination arm. Capecitabine (Xeloda®) and
docetaxel were interrupted and the dosages reduced by 25% in patients who experienced a
second occurrence of a given grade 2 toxicity, or any grade 3 toxicity, suggesting that the
starting dosages were perhaps too high.
The role of chemotherapy in metastatic head and neck cancer is limited to palliation of the
symptoms of disease. Platinum and 5-fluorouracil combinations remain standard first line
treatment strategies. The taxanes have been shown to have similar efficacy to such first
line regimens and are often used as salvage treatment for patients with metastatic disease.
Given that docetaxel has documented clinical efficacy in head and neck cancer and that there
are preclinical data to suggest synergy with docetaxel and capecitabine, it is reasonable to
consider using these agents in combination to treat head and neck cancer patients. Moreover,
capecitabine and docetaxel have distinct mechanisms of action and no overlap of key
toxicities. A recent phase I/II study by Tonkin, et al. in metastatic breast cancer patients
demonstrated activity and less toxicity when docetaxel 30 mg/m2/week (day 1 and 8 q21 days)
was combined with capecitabine 1800 mg/m2/day (14 of 21 days). In another phase I study by
Nadella, et al. weekly docetaxel (36 mg/m2 ) was combined with 14 days of capecitabine (up
to 1500 mg/m2/day) over a course of 28 days. Antitumor responses were observed in patients
with breast, colon, and bladder cancers. Hence, we propose this study whereby patients with
previously treated, metastatic/recurrent head and neck cancer will receive treatment with
docetaxel and capecitabine.
To reduce the potential for toxicity, we will use a modification of the Nadella regimen.
Docetaxel will be administered weekly at a dosage of 30 mg/m2 for 3 out of every 4 weeks and
capecitabine will be administered at a flat dosage of 2000 mg per day (1000 mg p.o. b.i.d.)
for two weeks out of every 4 weeks. The justification for using a flat dosage of
capecitabine versus a calculated dosage is based on pharmacokinetic data that show no change
in clearance of capecitabine with changes in BSA. We plan to use a fixed dose of 2000 mg qd
(1000 mg q am and 1000 mg q pm). Fixed dosing of capecitabine is convenient and feasible, as
shown in a prior University of Michigan study in breast cancer patients. In another study
Schott, et al. informally piloted the combination of weekly docetaxel 36 mg/m2 and 1500 mg
twice daily (3000 mg/day) x 14 days capecitabine in metastatic breast cancer patients, and
found it to be without unexpected or untoward side effects. Additionally, to take advantage
of the time course of upregulation of TP in the preclinical models, the capecitabine dose
will be given on days 5-18. In a flat dosing scheme, the Nadella regimen would have
administered an average dose of 2125 mg qd for 14 days, assuming an average BSA of 1.7 m2.
We plan to round this dosage downward to 2000 mg per day x 14 days; therefore, our regimen
will use a slightly lower dosage of capecitabine. We feel that our proposed slightly lowered
dose (closer to Nadella phase I dosing vs. Tonkin) of capecitabine is justified for the
following reasons:
1. The Nadella study was performed in a group of patients with solid tumor malignancies
that were refractory to conventional therapy or for whom no effective therapy existed.
ECOG performance status (PS) was 1 or 2 in 5/17 (30%) patients, 10/17 patients had
received 2 or more lines of previous chemotherapy, and 7/17 patients had received
previous radiotherapy. Based on data from previous treatment of head and neck cancer
patients at the University of Michigan, the patient population to be enrolled in this
trial is expected to be 60% PS 0 and 40% PS 1, and some will have received prior
chemotherapy and/or radiotherapy. Like the Nadella patient population, a majority of
our patients have been pretreated and are of poorer health.
2. Dose interruptions and modifications are built into the protocol so that appropriate
changes in treatment can be made in patients with Grade I or II toxicity, before the
toxicity becomes Grade III or greater. Since the docetaxel is given weekly, and the
capecitabine is administered daily, if patients are experiencing toxicity within a
cycle, the dose of either can be held or modified.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |